RE: RNS13 Nov 2020 07:38
CLINIGEN
Synairgen and Clinigen sign Managed Access Program agreement with SNG001 for treatment of hospitalised patients with COVID-19
Southampton and Burton-on-Trent, UK - 29 September, 2020: Synairgen plc (AIM: SNG, 'Synairgen'), the respiratory drug discovery and development company and Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company, have signed an agreement to launch a Managed Access Program for Synairgen's inhaled formulation of interferon beta (IFN-beta), SNG001, in the UK and the EU for the treatment of hospitalised COVID-19 patients.
This has just made their job a whole lot easier red hot phone lines today, "O by the way did I mention it's just received a positive peer review"